“Transmantle sign”を示す限局性皮質異形成における神経細胞の成熟と分化の未熟性：層特異的マーカー発現による解析

Transmantle dysplasia is a rare type of focal cortical dysplasia (FCD) characterized by expansion of the cortex from the deep white matter to the surface and in which there is a FCD IIA or IIB pathologic pattern. To characterize possible mechanisms underlying this regional disorder of radial migrating cells, we studied the expression patterns of neocortical layer-specific markers using immunohistochemistry in surgical specimens from 5 FCD IIA and 4 FCD IIB cases in children. All neuronal cells expressed the mature neuron marker MAP2/2B but not the microglia markers Iba-1 and CD68. Some layer-specific markers showed distinct expression patterns. TBR1-positive, SATB2-positive, and FOXP1-positive cells were diffusely distributed in the cortex and/or the white matter. TBR1-positive and FOXP1-positive cells were generally more numerous in FCD IIB than in FCD IIA and were mostly in the cortical molecular and upper layers. FOXP1-, FOXP2-, and CUTL1-positive cells also expressed the immature neuron marker, Nestin/PROX1, whereas TBR1-, CTIP2-, and SATB2-positive cells only expressed MAP2/2B. These data highlight differences between FCD IIB and FCD IIA with more cells having the immature marker in upper layer markers in the former. By analyzing layer-specific marker expression patterns, we identified apparent neuronal maturation differences between FCD IIA and FCD IIB in cases of transmantle dysplasia.博士（医学）・乙第1312号・平成25年5月29

Verification of Non-thermal Effects of 0.3–0.6 THz-Waves on Human Cultured Cells

Recent progress has been made in the development of terahertz (THz) waves for practical applications. Few studies that have assessed the biological effects of THz waves have been reported, and the data currently available regarding the safety of THz waves is inadequate. In this study, the effect of THz wave exposure on two cultured cells was assessed using a widely tunable THz source with a 0.3–0.6 THz frequency range, which can be used and increased in one GHz increments. The THz waves applied to the cultured cells were weak enough such that any thermal effects could be disregarded. The influence of THz wave exposure on both the proliferative and metabolic activities of these cells was investigated, as well as the extent of the thermal stress placed on the cells. In this work, no measurable effect on the proliferative or metabolic activities of either cell type was observed following the exposure to THz waves. No differences in the quantity of cDNA related to heat shock protein 70 was detected in either the sham or exposure group. As such, no differences in cellular activity between cells exposed to THz waves and those not exposed were observed

A new biomarker candidate for spinal muscular atrophy: Identification of a peripheral blood cell population capable of monitoring the level of survival motor neuron protein.

Spinal muscular atrophy (SMA) is a severe genetic neuromuscular disorder caused by insufficiency of functional survival motor neuron (SMN) protein. Several clinical trials have been conducted with the aim of upregulating the expression of the SMN protein in SMA patients. In order to evaluate the efficiency of these SMN-targeted approaches, it has become necessary to verify SMN protein levels in the cells of SMA patients. Accordingly, we have developed a method allowing the evaluation of the functional SMN protein with < 1.5 mL of peripheral blood using imaging flow cytometry. The expression of SMN protein in CD3+, CD19+, and CD33++ cells obtained from SMA patients, was significantly reduced compared with that in cells from control subjects. In spot analysis of CD33++ cells, the intensities of SMN spots were significantly reduced in SMA subjects, when compared with that in controls. Therefore, SMN spots implied the presence of functional SMN protein in the cell nucleus. To our knowledge, our results are the first to demonstrate the presence of functional SMN protein in freshly isolated peripheral blood cells. We anticipate that SMN spot analysis will become the primary endpoint assay for the evaluation and monitoring of therapeutic intervention, with SMN serving as a reliable biomarker of therapeutic efficacy in SMA patients